Tolvaptan for the treatment of liver cirrhosis oedema

Health-related quality of life and survival in Chinese patients with chronic liver disease

(2013) Feng Gao et al.   Health and Quality of Life Outcomes

Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial

(2013) Kiwamu Okita et al.   HEPATOLOGY RESEARCH

Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial

(2013) Isao Sakaida et al.   HEPATOLOGY RESEARCH

The Pharmacokinetics and Pharmacodynamics of Tolvaptan in Patients with Liver Cirrhosis with Insufficient Response to Conventional Diuretics: a Multicentre, Double-blind, Parallel-group, Phase III Study

(2013) I Sakaida et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema

(2013) Isao Sakaida et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

(2011) Susan E. Shoaf et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male Volunteers

(2011) Seong Ryul Kim et al.   CARDIOVASCULAR DRUGS AND THERAPY

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)

(2011) Masunori Matsuzaki et al.   CARDIOVASCULAR DRUGS AND THERAPY

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

(2011) Susan E. Shoaf et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis

(2011) Andrés Cárdenas et al.   JOURNAL OF HEPATOLOGY

A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis

(2010) Kiwamu Okita et al.   JOURNAL OF GASTROENTEROLOGY

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis

(2010) Florence Wong et al.   JOURNAL OF HEPATOLOGY

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis

(2010)   JOURNAL OF HEPATOLOGY

Effects of satavaptan, a selective vasopressin V2receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

(2008) Pere Ginès et al.   HEPATOLOGY

Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management

(2008) Pere Ginès et al.   HEPATOLOGY

Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List

(2008) W. Ray Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE